News

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.

The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.

The FDA approved the first oral treatments for paraganglioma, pheochromocytoma, and anal cancer in May.

Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data.

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.

The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free and overall survival.

Adding durvalumab to perioperative FLOT upped event-free survival in patients with gastric or gastroesophageal adenocarcinoma eligible for resection.

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with cisplatin/radiotherapy in LA-SCCHN.

Atezolizumab plus chemotherapy reduced risk of death or recurrence by 50% compared with chemotherapy alone for patients with stage III dMMR colon cancer.

Patients with stage III resected colon cancer had lower risk of death with less inflammatory diets and more regular physical activity.

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

T-DXd led to improvements in OS, PFS, ORR, and DOR compared with ramucirumab/paclitaxel in the second line for HER2-positive gastric and GEJ cancer.

Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Encorafenib and cetuximab plus mFOLFOX6 increased progression-free survival for patients with metastatic colorectal cancer harboring BRAF V600E mutations.

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.

Adding immunotherapy to chemo may boost pCR and downstaging rates in the neoadjuvant setting for muscle-invasive bladder cancer.

SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

The VENTANA MET (SP44) RxDx Assay is now FDA approved to identify patients with NSCLC eligible for telisotuzumab vedotin.

CRS and ICANS rates were similar in adults 75 years or older vs younger individuals with relapsed/refractory multiple myeloma.